<DOC>
	<DOCNO>NCT00600548</DOCNO>
	<brief_summary>The hypothesis trial therapeutic activity safety oral miltefosine Brazilian patient cutaneous leishmaniasis similar superior intravenous standard treatment ( meglumine antimoniate - Glucantime® ) .</brief_summary>
	<brief_title>Trial Miltefosine Cutaneous Leishmaniasis ( Brazil )</brief_title>
	<detailed_description />
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Newly diagnose ( untreated ) cutaneous leishmaniasis localize lesion visualization amastigotes tissue sample positive culture diagnose polymerase chain reaction ( PCR ) method intradermal skin testing ( Montenegro test ) . Number lesion : 1 5 ulcerative lesion . Lesion´s diameter : 1 5 cm . Disease duration : three month . Safety concern : Thrombocyte count &lt; 30 x 109/l Leukocyte count &lt; 1 x 109/l Hemoglobin &lt; 5 g/100 ml ASAT , ALAT , AP &gt; 3 time upper limit normal range Bilirubin &gt; 2 time upper limit normal range Serum creatinine BUN &gt; 1.5 time upper limit normal range Evidence serious underlie disease ( cardiac , renal , hepatic pulmonary ) Immunodeficiency antibody HIV Any noncompensated uncontrolled condition , active tuberculosis , malignant disease , severe malaria , HIV , major infectious disease Lactation , pregnancy ( determined adequate test ) inadequate contraception female childbearing potential treatment period plus 2 month Lack suitability trial : Negative parasitology ( aspirate/smear ) negative Montenegro test Any history prior antileishmania therapy Any condition compromise ability comply study procedure Concomitant serious infection cutaneous Administrative reason : Lack ability willingness give inform consent ( patient and/or parent / legal representative ) Anticipated nonavailability study visits/procedures</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Meglumine antimoniate</keyword>
	<keyword>L. braziliensis , L. guyanensis</keyword>
</DOC>